Saltar para: Post [1], Pesquisa e Arquivos [2]

Noticias de Crohn - Copy.png

Resumo na língua original:

French biotech, Enterome, has developed an oral, microbiome therapy to combat Crohn’s disease. Many researchers are turning to the microbiome, as they believe the field could hold the key to human health. The candidate, EB8018 has demonstrated good tolerability at a range of doses and that it remains in the gut during a Phase I study. The company is now in the process of initiating a Phase Ib trial to investigate the drug’s safety, pharmacokinetics and efficacy that would support a Phase II study planned for next year.






Ler artigo original


Autoria e outros dados (tags, etc)

publicado às 11:00


  Pesquisar no Blog

Subscrever por e-mail

A subscrição é anónima e gera, no máximo, um e-mail por dia.